<DOC>
	<DOCNO>NCT01469156</DOCNO>
	<brief_summary>This Phase I/II study investigate safety tolerability intravitreally administer 0.5mg 2.0mg Ranibizumab three monthly dos follow 9 month period criteria-based , as-needed retreatment 12 month drug safety follow subject exudative polypoidal choroidal vasculopathy ( PCV ) total 24 month .</brief_summary>
	<brief_title>Safety Study 2.0mg Lucentis Treat Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>Twenty eye randomize receive 3 consecutive monthly intravitreal 2.0 mg/0.5mg ( 3:1 ratio ) Ranibizumab injection first injection occur Day 0 second third injection occur month 1 month 2 respectively . Retreatment intravitreal Ranibizumab therapy investigator discretion guideline recommend retreatment .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Males Females &gt; 18 year age . Females child bear potential undergo urine pregnancy test require use appropriate method birth control . ICG fluorescein angiographic characteristic consistent active , leak PCV subfoveal lesion and/or subfoveal hemorrhage , lipid exudate , PED fluid diagnose within past 6 month diagnose newly active within past 6 month . Subjects complete 24 month follow original FVF3671s protocol may enter study without necessarily demonstrate active exudative PCV enrollment . BestCorrected ETDRS Visual Acuity 4 meter 20/20 20/800 . Lesion size limitation . Lesions Characteristics leak lesion consistent PCV . No limitation hemorrhage , fibrosis atrophy . No therapy ( include non foveal laser , PDT , intravitreal steroid , TTT , radiotherapy , antiVEGF therapy ) intraocular surgery within past 30 day condition . Clear ocular medium allow photography/angiography . Ability provide write informed consent comply study assessment full duration study . Patients feature age relate macular degeneration abundant drusen demographic feature consistent diagnosis . Allergy Fluorescein , ICG , Iodine , Shellfish . Pregnancy ( positive pregnancy test ) Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Participation another simultaneous medical investigation trial . Exclude antiVEGF agent therapy option . History previous subfoveal laser . Advanced glaucoma ( IOP &gt; 25 cup/disc ration &gt; 0.8 ) Any condition opinion investigator would interfere disease status/progression jeopardize patient ' participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>polypoidal choroidal vasculopathy</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>Lucentis</keyword>
</DOC>